MEDICAL POLICY – 7.01.159
Sphenopalatine Ganglion Block for Headache

BCBSA Ref. Policy: 7.01.159
Effective Date: Feb. 1, 2019
Last Revised: Jan. 22, 2019
Replaces: N/A

RELATED MEDICAL POLICIES:
7.01.125 Occipital Nerve Stimulation

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | CODING | RELATED INFORMATION
EVIDENCE REVIEW | REFERENCES | HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

Introduction

The sphenopalatine ganglion (SPG) is a group of nerve cells behind the nose. This nerve bundle is linked to the trigeminal nerve, which has three branches going to the eye area and the upper and lower jaws. The trigeminal nerve is the main nerve linked to headache disorders. A new type of treatment has been proposed to address headaches and facial pain. In this treatment, a hollow tube (a catheter) is inserted into the nose and maneuvered near the SPG. Once the catheter is in place, topical anesthesia is applied. The goal is to use the anesthesia as a way to block pain signals. This treatment is unproven (investigational). Larger, high-quality studies are needed to determine how effective this treatment is in the long term and how it compares to standard treatment for severe acute, migraine, and cluster headaches.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria
Procedure

Sphenopalatine ganglion blocks

Investigational

Sphenopalatine ganglion blocks are considered investigational for all indications, including but not limited to the treatment of migraines and non-migraine headaches.

Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>Unlisted procedure, nervous system</td>
</tr>
</tbody>
</table>

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

N/A

Evidence Review

Description

Chronic migraine and severe headaches are common conditions and the available treatments are not universally effective. A proposed treatment option is blocking the sphenopalatine ganglion (SPG) by applying topical anesthetic intranasally to it. Several catheters approved by the Food and Drug Administration are available for the SPG blocking procedure.
Background

**Headaches and Headache Treatments**

Headaches are common neurologic disorders and are among the top reasons for which patients seek medical care. Headaches affect approximately 50% of the general population in a given year and over 90% of people have a lifetime history of headache.\(^1\) The two most common types of headache are migraines and tension-type headaches.

Migraines are the second-most common headache disorder, with a 1-year migraine prevalence of approximately 12% in the United States.\(^2\) They are characterized by severe pain on one or both sides of the head, nausea, and, at times, disturbed vision. Migraines can be categorized by headache frequency and by the presence or absence of aura. Chronic migraine is defined as attacks on at least 15 days per month for more than 3 months, with features of migraine on at least 8 days per month.\(^3\)

Tension headaches have a prevalence of approximately 40%.\(^2\) Diagnostic criteria include the presence of at least two of the following characteristics: bilateral headache location, nonpulsating pain, mild-to-moderate intensity, and headache not aggravated by physical activity.\(^3\)

Cluster headaches are less common than tension or migraine headaches, with an estimated prevalence of 0.1% of the population.\(^2\) They are characterized by severe unilateral orbital, supraorbital, and/or temporal pain that also includes other symptoms in the eye and/or nose on the same side (eg, rhinorrhea, eyelid edema or drooping).

**Treatment**

A variety of medications are used to treat acute migraine episodes. They include medications taken at the onset of an attack to abort the attack (triptans, ergotamines) and medications to treat the pain and other symptoms of migraines once they are established (nonsteroidal anti-inflammatory drugs, antiemetics). Prophylactic medication therapy may be appropriate for people with migraines that occur more than 2 days per week. In addition to medication, behavioral treatments (eg, relaxation, cognitive therapy) are used to manage migraine headache. Botulinum toxin type A injections are a U.S. Food and Drug Administration–approved treatment for chronic migraine.

Severe acute cluster headaches may be treated with abortive therapy including, breathing 100% oxygen and triptan medications. Other medications used to treat cluster headaches include
steroids, calcium channel blockers, and nerve pain medications. Due to the severity of pain associated with cluster headaches, patients may seek emergency treatment. Tension-type headaches are generally treated with over the counter pain medication.

**Sphenopalatine Ganglion Block**

Sphenopalatine ganglion (SPG) blocks are a proposed treatment option for chronic migraines and some severe non-migraine headaches. The SPG is a group of nerve cells located behind the bony structures of the nose. The nerve bundle is linked to the trigeminal nerve, the primary nerve involved in headache disorders. The SPG has both autonomic nerves, which in this case are associated with functions such as tearing and nasal congestion, and sensory nerves, associated with pain perception. SPG blocks involve topical application of local anesthetic to mucosa overlying the SPG. The rationale for using SPG blocks to treat headaches is that local anesthetics in low concentrations could block the sensory fibers and thereby reduce pain while maintaining autonomic function.

The proposed procedure for SPG blockade is to intranasally insert a catheter that is attached to a syringe carrying local anesthetic (eg, lidocaine, bupivacaine). Once the catheter is in place, the local anesthetic is topically applied to the posterior wall of the nasal cavity to reach the SPG. Originally, SPG blocks were done by inserting a cotton-tipped applicator dabbed with local anesthetic into the nose; this technique may be less accurate and effective than the currently proposed procedure. Neurostimulation of the SPG and SPG blockade with radiofrequency lesioning have been used outside of the United States, but these treatments are not cleared or approved by FDA.

Three catheter devices are commercially available in the United States for performing SPG blocks. The catheters have somewhat different designs but all are attached to syringes that deliver local anesthetic. The catheters are inserted intranasally and, once in place, the local anesthetic is topically applied through the catheter. With 2 of the 3 commercially available catheters (the SpenoCath®, Allevio™), patients are positioned on their back with their nose pointed vertically and their head turned to the side. With the Tx360® device, patients remain seated.

The company marketing the Tx360® device proposes its use in the context of the MiRx™ protocol. This 2-part protocol includes a medical component for immediate pain relief and a physical component to reduce headache recurrences. The medical component involves clinical evaluation and, if the patient is considered eligible, an SPG block procedure. The physical
component can include any of a number of approaches such as physical therapy, ergonomic modifications, massage, and dietary recommendations.

The optimal number and frequency of SPG treatments is unclear. Information from the American Migraine Foundation suggests that the procedure can be repeated as often as needed to control pain.\textsuperscript{5} A randomized controlled trial has described a course of treatment for migraines consisting of SPG blocks twice a week for 6 weeks (total, 12 treatments).

SGB blocks are proposed for both short-term and long-term treatment of headaches and migraines. When used in the emergency setting in patients with severe acute headaches, the goal of treatment is to abort the current headache while the patient is in the emergency department. In the randomized controlled trial that provided a 6-week course of treatment with SPG blocks for chronic migraine (mentioned above), short-term outcomes were assessed up to 24 hours after each treatment, and the duration and frequency of chronic migraines were assessed at 1 and 6 months after the course of treatment.

**Summary of Evidence**

For individuals who have chronic migraine who receive SPG block(s), the evidence includes a randomized controlled trial (RCT) and a case report. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The randomized trial evaluated a regimen of 12 SPG blocks over 6 weeks and was double-blind and placebo-controlled. The trial found significantly greater short-term (up to 24 hours) benefits from active treatment than from placebo. There were no significant longer term effects (ie, 1 and 6 months after 12 treatments), although the trial was underpowered to detect longer term efficacy. Given that SPG blocks are being proposed as a preventive therapy for chronic migraines, evidence demonstrating reduced migraine frequency, severity, or other objective outcomes from robust trials is still needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have severe acute headache treated in the emergency setting who receive SPG block(s), the evidence includes 1 RCT. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The randomized, double-blind, placebo-controlled trial evaluated a single SPG block for severe acute headache of mixed etiologies. There was no statistically significant difference between active treatment and placebo for the primary outcome (pain reduction 15 minutes postintervention). The trialists did not collect pain data again until 24 hours posttreatment, at which time significantly more patients were headache-free in the active treatment arm than in the placebo arm. Additional studies,
preferably RCTs, are needed to determine whether SPG blocks are an effective treatment in the emergency setting. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have cluster headache who receive SPG block(s), the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Two small case series, both of which evaluate an approach for intranasal SPG blocks that differ from the intervention currently available in the United States, were identified. In these series, 40% to 50% of patients experienced complete symptom relief for a variable length of time and about 20% had treatment-related complications. However, it is not clear from these series the degree to which the procedures evaluated differ in safety and efficacy from an intranasal SPG block using a device cleared by the U.S. Food and Drug Administration. Additional studies, preferably RCTs, are needed to evaluate SPG blocks for treating cluster headaches. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 1.

**Table 1. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02090998</td>
<td>Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines</td>
<td>200</td>
<td>July 2021</td>
</tr>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02365909</td>
<td>Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)</td>
<td>6</td>
<td>Aug 2016 (terminated)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial

**Practice Guidelines and Position Statements**

No guidelines or statements were identified.
Medicare National Coverage

There is no national coverage determination.

Regulatory Status

The Tx360® Nasal Applicator (Tian Medical), the Allevio™ SPG Nerve Block Catheter (JET Medical), and the SpenoCath® (Dolor Technologies) are considered class I devices by the U.S. Food and Drug Administration and are exempt from 510(k) requirements. This classification does not require submission of clinical data on efficacy but only notification of Food and Drug Administration prior to marketing. All 3 devices are used to apply numbing medication intranasally.

References


**History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/17</td>
<td>New Policy, approved July 18, 2017, add to Surgery section. Policy created with literature review through March 23, 2017. Sphenopalatine ganglion blocks are considered investigational for all indications, including but not limited to the treatment of migraines and non-migraine headaches.</td>
</tr>
<tr>
<td>09/12/18</td>
<td>Coding update, added CPT code 64505.</td>
</tr>
<tr>
<td>10/05/18</td>
<td>Coding update, removed CPT code 64505.</td>
</tr>
<tr>
<td>12/01/18</td>
<td>Annual Review, approved November 21, 2018. Policy updated with literature review through September 2018; no references were added. Policy statement unchanged.</td>
</tr>
<tr>
<td>02/01/19</td>
<td>Annual Review, approved January 22, 2019. Policy updated with literature review through September 2018; no references were added. Policy statement unchanged.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2019 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination Is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5952, TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action because of race, color, national origin, age, disability or sex.

Call 800-722-1471 (TTY: 800-842-5357).

Arabic (Arabic):

يحيى هذا الإشعار ضروري. قد يحيى هذا الإشعار المعلومات مهمة بخصوص طلب أو قرر توصيف الحياة التي تتطلب الحصول عليها من خلال Premera Blue Cross. الوقاية من هذه الخدمات أو تأجيل حصولك على هذه المعلومات المهمة قد يكون نوعياً بالطريقة المعروفة في هذه الإشارة، وقد تحتاج إجراء أخرى في توفيرية النزاع لتحديد تأثير أي مساعدة في ذلك الطلب. يجري كل الحصول على هذه المعلومات والمساعدة بكل تكلفة دون تكيد أي تكلفة أخرى.

800-722-1471 (TTY: 800-842-5357) 800-722-1471 (TTY: 800-842-5357)

Oromo (Cushite):


Lakhoofoosa bilbiaa 800-722-1471 (TTY: 800-842-5357) tii bilbiaa.

Deutsche (German):


Hmoob (Hmong):

Tsb nbawj twaj xoh no moj cov ntsib laj tseem ceeb. Tej zauv tsawv twaj xoh no moj cov ntsib laj tseem ceeb bxog xo jay dtauv thov kaj prov no yooj kaj cov kaj prov caap no jay dtsawv Premera Blue Cross. Tej zauv moj cov lbh tseem ceeb caap xoh ruu hauv dtauv no. Tej zauv moj kaj jaij ruu taau qee yam jaij ruu bep kaj xo jaij tsup bhaub cov cajj nyoy uas teev bhaub ruu hauv dtauv mox no mas kaj jaij ruu taub baij prov caap kaj dtauv hauv nyoy kaj prov bep jaij kaj cajj ruu baij.

Hu rau 800-722-1471 (TTY: 800-842-5357).

Ilokano (Ilocano):

Daytoy a Pakdaar ket naglaon iti Napateg nga Impormasion. Daytoy a pakdaar mabalin nga adda ket naglaon iti napateg nga impormasion maiyanggep iti aplikasyonyo wenno coverage babaen iti Premera Blue Cross. Daytoy ket mabalin dagiti importante a pelta iti daytoy a pakdaar. Mabalin nga adda rumbeng nga aramidenyo nga addang sakkay dagiti partikular a naituding nga aldın tapno mapagtalaineyo ti coverage ti salu-tayo wenno tulong kadagit gastos. Adda karbenganyo a mangala iti daytoy nga impormasion ken tulong iti bukodyo a pagasasao nga awan ti bayadangyo. Tumawag iti numero nga 800-722-1471 (TTY: 800-842-5357).

Italiano (Italian):

Questo avviso contiene informazioni importanti. Questo avviso può contenere informazioni importanti sulla tua domanda o copertura attraverso Premera Blue Cross. Potrebbero esserci date chiave in questo avviso. Potrebbe essere necessario un tuo intervento entro una scadenza determinata per consentirti di mantenere la tua copertura o sovvenzione. Hai il diritto di ottenere queste informazioni e assistenza nella tua lingua gratuitamente.

Chiamata 800-722-1471 (TTY: 800-842-5357).
Premera Blue Cross (TTY: 800-842-5357) may also be called Precarise Blue Cross, Blue Cross Care, or Premera Blue. You may receive a call or other communication from us to provide important information about coverage benefits and costs. If you need to make any decisions about your health care or health insurance coverage, please review the information provided to you. If you have any questions, you can call us at 800-722-1471 (TTY: 800-842-5357).

Contact Us:
Send a message to customer service or speak with a representative by calling 800-722-1471 (TTY: 800-842-5357) at any time.

Premera Blue Cross has received complaints of auto-dialer calls that are not providing the required contact information or disconnection before the caller has a chance to be heard. This includes not providing the name and phone number of the representative to whom they are speaking or not giving the caller the opportunity to say they do not wish to receive the call.

We are committed to providing you trustworthy and reliable customer service. If you have experienced this with us, please call 800-722-1471 (TTY: 800-842-5357) immediately.

If you would like to file a complaint about Premera Blue Cross, the complaint can be filed with:

- The U.S. Department of Health and Human Services Office of Civil Rights
- The U.S. Department of Health and Human Services Office of Inspector General
- The Centers for Medicare & Medicaid Services (CMS) Ombudsman Program
- A state insurance or healthcare department

You can file a complaint online or by phone. You can also file a complaint by mail or fax.